Antineoplastic Agents, Hormonal

"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Descriptor ID	D018931
MeSH Number(s)	D27.505.954.248.169
Concept/Terms	Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Hormonal Agents, Antineoplastic Hormonal Antineoplastic Agents Hormonal Antineoplastics Antineoplastic Hormonal Drugs Drugs, Antineoplastic Hormonal Hormonal Drugs, Antineoplastic Hormonal Antineoplastic Drugs Antineoplastics, Hormonal Antineoplastic Hormonal Agents Agents, Antineoplastic Hormonal Antineoplastic Drugs, Hormonal

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Hormonal [D27.505.954.248.169]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Hormonal".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.

Bar chart showing 47 publications over 20 distinct years, with a maximum of 7 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	1	3	4
1998	1	0	1
2000	0	1	1
2001	1	0	1
2002	0	2	2
2003	1	1	2
2004	1	4	5
2005	1	3	4
2006	0	1	1
2007	1	2	3
2008	1	0	1
2009	1	1	2
2010	0	3	3
2011	2	5	7
2012	1	1	2
2013	1	1	2
2015	0	2	2
2016	1	0	1
2017	1	0	1

Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.

Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 May 01; 123(9):1536-1544.

View in: PubMed
Cristofanilli M. Metastatic breast cancer: focus on endocrine sensitivity. Lancet. 2016 12 17; 388(10063):2961-2962.

View in: PubMed
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. Breast Cancer Res Treat. 2015 Dec; 154(3):533-41.

View in: PubMed
Maarouf OH, Aravamudhan A, Rangarajan D, Kusaba T, Zhang V, Welborn J, Gauvin D, Hou X, Kramann R, Humphreys BD. Paracrine Wnt1 Drives Interstitial Fibrosis without Inflammation by Tubulointerstitial Cross-Talk. J Am Soc Nephrol. 2016 Mar; 27(3):781-90.

View in: PubMed
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.

View in: PubMed
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38.

View in: PubMed
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI. Contemporary grading for prostate cancer: implications for patient care. Eur Urol. 2013 May; 63(5):892-901.

View in: PubMed
Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 1; 30(13):1534-40.

View in: PubMed
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 1; 118(17):4139-47.

View in: PubMed
Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement